⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 29, 2021Journal of Clinical MicrobiologyOpen Access

Evaluation of MicroScan WalkAway for Determination of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility in Carbapenem-Resistant Gram-Negative Bacilli

View Full Paper

Ask AI

Bookmark

Share

Abstract

We evaluated the performance of ceftazidime-avibactam and ceftolozane-tazobactam MicroScan Neg multidrug-resistant MIC 1 (NMR1) panel for clinical carbapenem-nonsusceptible Gram-negative bacilli isolates. We evaluated 212 clinically significant carbapenem-nonsusceptible Gram-negative bacilli (139 Pseudomonas aeruginosa and 73 KPC-producing Enterobacterales ) from 71 Brazilian hospitals (2013 to 2020).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

A 2021 study studied this question.

synapsesocial.com/papers/6ab35d998b15d86222f386e4 https://doi.org/10.1128/jcm.01536-21

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Epidemiology of carbapenem-resistant Gram-negative infections globallyOriginal Research · 2019 · 214 citations
2Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000–2017Retrospective Study · 2020 · 66 citations
3In vitro activity of ceftolozane–tazobactam and ceftazidime–avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre studyOriginal Research · 2019 · 34 citations
4New Carbapenemase Inhibitors: Clearing the Way for the β-LactamsClinical Trial · 2020 · 122 citations
5New β-Lactam–β-Lactamase Inhibitor CombinationsReview · 2020 · 525 citations

More related papers

Evaluation of in vitro activity of ceftolozane–tazobactam against recent clinical bacterial isolates from Brazil – the EM200 study2020
Advances in Rapid Identification and Susceptibility Testing of Bacteria in the Clinical Microbiology Laboratory: Implications for Patient Care and Antimicrobial Stewardship Programs2017
Antimicrobial susceptibility testing: currently used methods and devices and the near future in clinical practice2020

More from Journal of Clinical Microbiology

Performance evaluation of antimicrobial susceptibility testing devices across CLSI, EUCAST, ISO, FDA, and EMA frameworks: implications for breakpoint applicationTue,
Comparison of antimicrobial susceptibility testing methods for aztreonam-avibactam against NDM-producing Enterobacterales clinical isolatesMon,